Esperion Therapeutics (ESPR) said Thursday it has signed a licensing deal with Neopharm Israel for the exclusive rights to commercialize cholesterol medications Nexletol and Nexlizet in Israel.
Under the terms of the agreement, Esperion will grant Neopharm exclusive commercialization rights to the drugs in Israel, Gaza, and the West Bank.
In return, Esperion will receive upfront and near-term milestone payments, and will be eligible to receive tiered royalties on sales of the drugs in Israel.
Price: 2.62, Change: -0.07, Percent Change: -2.79
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。